XELOX方案与FOLFOX方案治疗转移性结直肠癌的比较：一项更新的荟萃分析。
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
作者信息
Guo Yu, Xiong Bing-Hong, Zhang Tao, Cheng Yong, Ma Li
机构信息
a Department of Gastrointestinal Surgery , First Affiliated Hospital of Chongqing Medical University , Chongqing , China.
b Department of Gastrointestinal and Hernia Surgery , First Affiliated Hospital of Kunming Medical University, No. 1 School of Clinical Medicine, Kunming Medical University , Kunming , China.
出版信息
Cancer Invest. 2016;34(2):94-104. doi: 10.3109/07357907.2015.1104689. Epub 2016 Feb 11.
This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included. A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group. For mCRC, the effect of XELOX is similar to FOLFOX.
本荟萃分析旨在评估以XELOX（卡培他滨加奥沙利铂）与FOLFOX（氟尿嘧啶加奥沙利铂）作为转移性结直肠癌（mCRC）治疗方案时在疗效和安全性方面的差异。仅纳入比较XELOX与FOLFOX的随机对照试验（RCT）。共有来自八项RCT的4363例患者可供分析。汇总分析显示，两组在总生存期（OS）和客观缓解率（ORR）方面无统计学差异。XELOX组血小板减少症、手足综合征和腹泻的发生率较高，而FOLFOX组中性粒细胞减少症的发生率较高。对于mCRC，XELOX的疗效与FOLFOX相似。
Zotero 插件